Skip to main content
Top
Published in: Virchows Archiv 3/2018

Open Access 01-03-2018 | Original Article

Gastric cancer: immunohistochemical classification of molecular subtypes and their association with clinicopathological characteristics

Authors: Eva-Maria Birkman, Naziha Mansuri, Samu Kurki, Annika Ålgars, Minnamaija Lintunen, Raija Ristamäki, Jari Sundström, Olli Carpén

Published in: Virchows Archiv | Issue 3/2018

Login to get access

Abstract

Gastric cancer is traditionally divided into intestinal and diffuse histological subtypes, but recent molecular analyses have led to novel classification proposals based on genomic alterations. While the intestinal- and diffuse-type tumours are distinguishable from each other at the molecular level, intestinal-type tumours have more diverse molecular profile. The technology required for comprehensive molecular analysis is expensive and not applicable for routine clinical diagnostics. In this study, we have used immunohistochemistry and in situ hybridisation in molecular classification of gastric adenocarcinomas with an emphasis on the intestinal subtype. A tissue microarray consisting of 244 gastric adenocarcinomas was constructed, and the tumours were divided into four subgroups based on the presence of Epstein-Barr virus, TP53 aberrations and microsatellite instability. The intestinal- and diffuse-type tumours were separately examined. The distribution of EGFR and HER2 gene amplifications was studied in the intestinal-type tumours. Epstein-Barr virus positive intestinal-type tumours were more common in male patients (p = 0.035) and most often found in the gastric corpus (p = 0.011). The majority of the intestinal-type tumours with TP53 aberrations were proximally located (p = 0.010). All tumours with microsatellite instability showed intestinal-type histology (p = 0.017) and were associated with increased overall survival both in the univariate (p = 0.040) and multivariate analysis (p = 0.015). In conclusion, this study shows that gastric adenocarcinomas can be classified into biologically and clinically different subgroups by using a simple method also applicable for clinical diagnostics.
Literature
1.
go back to reference Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin D, Forman D, Bray F (2013) GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, International Agency for Research on Cancer http://globocan.iarc.fr. Accessed on 23 April 2017 Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin D, Forman D, Bray F (2013) GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, International Agency for Research on Cancer http://​globocan.​iarc.​fr. Accessed on 23 April 2017
2.
go back to reference Laurén P (1965) The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64:31–49CrossRefPubMed Laurén P (1965) The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64:31–49CrossRefPubMed
4.
go back to reference Cristescu R, Nebozhyn M, Kim K, Ting J, Wong S, Liu J, Yue Y, Wang J, Yu K, Ye X, Do I, Liu S, Gong L, Fu J, Jin J, Choi M, Sohn T, Lee J, Bae J, Kim S, Park S, Sohn I, Jung S, Tan P, Chen R, Hardwick J, Kang W, Ayers M, Hongyue D, Reinhard C, Loboda A, Aggarwal A (2015) Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med 21:449–456. https://doi.org/10.1038/nm.3850 CrossRefPubMed Cristescu R, Nebozhyn M, Kim K, Ting J, Wong S, Liu J, Yue Y, Wang J, Yu K, Ye X, Do I, Liu S, Gong L, Fu J, Jin J, Choi M, Sohn T, Lee J, Bae J, Kim S, Park S, Sohn I, Jung S, Tan P, Chen R, Hardwick J, Kang W, Ayers M, Hongyue D, Reinhard C, Loboda A, Aggarwal A (2015) Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med 21:449–456. https://​doi.​org/​10.​1038/​nm.​3850 CrossRefPubMed
6.
go back to reference Kim HS, Shin S, Beom S, Jung M, Choi Y, Son T, Kim H, Cheong J, Hyung W, Noh S, Park J, Shin S, Lee S, Lee Y, Koom W, Lim J, Chung H, Rha S (2016) Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. Oncotarget 7:44608–44620. 10.18632/oncotarget.10115 PubMedPubMedCentral Kim HS, Shin S, Beom S, Jung M, Choi Y, Son T, Kim H, Cheong J, Hyung W, Noh S, Park J, Shin S, Lee S, Lee Y, Koom W, Lim J, Chung H, Rha S (2016) Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. Oncotarget 7:44608–44620. 10.​18632/​oncotarget.​10115 PubMedPubMedCentral
7.
8.
10.
go back to reference Bosman F, Carneiro F, Hruban R, Theise N (2010) WHO classification of tumours of the digestive system, 4th edn. IARC Press, Lyon Bosman F, Carneiro F, Hruban R, Theise N (2010) WHO classification of tumours of the digestive system, 4th edn. IARC Press, Lyon
14.
go back to reference Ålgars A, Avoranta T, Österlund P, Lintunen M, Sundström J, Jokilehto T, Ristimäki A, Ristamäki R, Carpén O (2014) Heterogeneous EGFR gene copy number increase is common in colorectal cancer and defines response to anti-EGFR therapy. PLoS One 18, 9(6):e99590. https://doi.org/10.1371/journal.pone.0099590 Ålgars A, Avoranta T, Österlund P, Lintunen M, Sundström J, Jokilehto T, Ristimäki A, Ristamäki R, Carpén O (2014) Heterogeneous EGFR gene copy number increase is common in colorectal cancer and defines response to anti-EGFR therapy. PLoS One 18, 9(6):e99590. https://​doi.​org/​10.​1371/​journal.​pone.​0099590
20.
go back to reference Lordick F, Kang Y, Chung H, Salman P, SC O, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Götte H, Melezínková H, Moehler M (2013) Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 14:490–499. https://doi.org/10.1016/S1470-2045(13)70102-5 CrossRefPubMed Lordick F, Kang Y, Chung H, Salman P, SC O, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Götte H, Melezínková H, Moehler M (2013) Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 14:490–499. https://​doi.​org/​10.​1016/​S1470-2045(13)70102-5 CrossRefPubMed
21.
go back to reference Waddell T, Chau I, Cunningham D, Gonzalez D, Frances A, Okines C, Wotherspoon A, Saffery C, Middleton G, Wadsley J, Ferry D, Mansoor W, Crosby T, Coxon F, Smith D, Waters J, Iveson T, Falk S, Slater S, Peckitt C, Barbachano Y (2013) Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 14:481–489. https://doi.org/10.1016/S1470-2045(13)70096-2 CrossRefPubMedPubMedCentral Waddell T, Chau I, Cunningham D, Gonzalez D, Frances A, Okines C, Wotherspoon A, Saffery C, Middleton G, Wadsley J, Ferry D, Mansoor W, Crosby T, Coxon F, Smith D, Waters J, Iveson T, Falk S, Slater S, Peckitt C, Barbachano Y (2013) Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 14:481–489. https://​doi.​org/​10.​1016/​S1470-2045(13)70096-2 CrossRefPubMedPubMedCentral
Metadata
Title
Gastric cancer: immunohistochemical classification of molecular subtypes and their association with clinicopathological characteristics
Authors
Eva-Maria Birkman
Naziha Mansuri
Samu Kurki
Annika Ålgars
Minnamaija Lintunen
Raija Ristamäki
Jari Sundström
Olli Carpén
Publication date
01-03-2018
Publisher
Springer Berlin Heidelberg
Published in
Virchows Archiv / Issue 3/2018
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-017-2240-x

Other articles of this Issue 3/2018

Virchows Archiv 3/2018 Go to the issue